Mankind Pharma Reports Strong Q2 FY27 With PAT Up 37.7% YoY
Mankind Pharma Ltd 路 Press Release 路 26 Oct 2026, 8:56 pm
Mankind Pharma Reports Strong Q2 FY27 With PAT Up 37.7% YoY Mankind Pharma reported a 17.3% YoY rise in consolidated revenue to INR 4,338 Cr for Q2 FY27, supported by a 14.8% increase in domestic revenue to INR 3,657 Cr and a 32.7% surge in exports to INR 681 Cr. EBITDA grew 27.2% YoY to INR 1,175 Cr with margins expanding 210 bps to 27.1%, while PAT jumped 37.7% YoY to INR 716 Cr. H1 FY27 revenue reached INR 8,368 Cr, up 15.1% YoY, with PAT at INR 1,290 Cr. Growth was driven by outperformance in chronic and acute domestic portfolios.
Original exchange filing (PDF)
More announcements from Mankind Pharma Ltd
- Please find attached intimation regarding change in Corporate Office Address of RTA 路 13 Nov 2026
- Please find attached Intimation of participation in the Investor Conference 路 06 Nov 2026
- Please find attached intimation regarding ESG Rating 路 05 Nov 2026
- Intimation of participation in the Investor Conference. 路 03 Nov 2026
- Please find attached transcript of the Earnings Conference Call for Q2 & H1 FY27 路 30 Oct 2026
- Please find attached intimation regarding re-affirmation/withdrawl of Credit Rating by CRISIL 路 30 Oct 2026
- In continuation of our earlier intimation dated October 22, 2026 please find attached the Investor Presentation to be made during the said Analyst / Institutional Investors meet 路 27 Oct 2026
- Please find attached link for audio recording of the Investor Conference Call held on October 26, 2026 路 27 Oct 2026
